The lawsuit, filed by Robbins LLP, claims Fractyl misled shareholders regarding the effectiveness of its Revita DMR System—a procedural therapy designed to treat type 2 diabetes and obesity. Plaintiffs allege that the company failed to disclose operational issues at clinical sites that compromised the integrity of the REMAIN-1 Midpoint Cohort results, leading to an overstatement of the therapy's commercial potential.

On January 29, 2026, the company revealed that patients treated with Revita experienced a 4.5% weight regain, a result that fell short of investor expectations. During an investor call that same day, CEO Harith Rajagopalan attributed the poor performance to study site irregularities. The market reaction was swift: the stock plummeted by 68.03% to close at $0.585. Following a subsequent downgrade by Morgan Stanley, the share price dropped another 21.7% the following day. Investors interested in the litigation can contact Robbins LLP, which operates on a contingency fee basis, before the upcoming court-mandated deadline.